Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation

Purpose: Previous gene expression studies have shown that fibroblast growth factor receptor 3 (FGFR3) is overexpressed in early stages of bladder cancer. To study the potential use of therapeutic antibodies against FGFR3, we have produced a collection of human single-chain Fv (scFv) antibody fragmen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2005-09, Vol.11 (17), p.6280-6290
Hauptverfasser:	MARTINEZ-TORRECUADRADA, Jorge, CIFUENTES, Gabriela, LOPEZ-SERRA, Paula, SAENZ, Pilar, MARTINEZ, Antonio, CASAL, J. Ignacio
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Antibodies, Blocking - therapeutic use Antibodies, Monoclonal - immunology Antineoplastic agents Biological and medical sciences bladder carcinoma blocking antibodies Cell Proliferation Enzyme-Linked Immunosorbent Assay FGFR3 Flow Cytometry human scFvs Humans Immunoglobulin Variable Region - genetics Immunoglobulin Variable Region - immunology Immunoprecipitation Medical sciences Molecular Sequence Data Nephrology. Urinary tract diseases Peptide Library Pharmacology. Drug treatments Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - immunology Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - immunology Receptor, Fibroblast Growth Factor, Type 1 Receptor, Fibroblast Growth Factor, Type 3 Receptors, Fibroblast Growth Factor - genetics Receptors, Fibroblast Growth Factor - immunology Recombinant Proteins - immunology Sequence Homology, Amino Acid Surface Plasmon Resonance Tumors of the urinary system Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - pathology Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!